Cardiovascular effects of empagliflozin in diabetes mellitus
Not Applicable
Completed
- Conditions
- Heart disease in patients with type 2 diabetes and previous myocardial infarctionCirculatory System
- Registration Number
- ISRCTN82391603
- Lead Sponsor
- niversity of Leeds
- Brief Summary
2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/34182806/ (added 13/08/2021)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
1. Type 2 diabetes mellitus
2. Metformin as single or dual therapy
3. Recent heart attack (<12 months)
4. HbA1c >48mmol/ml
5. 18-84 years old
6. Ability to provide informed consent
Exclusion Criteria
1. Previous coronary artery bypass grafting (CABG)
2. Need for further revascularisation
3. Contra-indication to CMR scanning (some pacemakers, intraorbital debris, intraauricular implants, intracranial clips etc)
4. Contra-indication to Adenosine
5. Known allergy to contrast medium (gadolinium)
6. Renal dysfunction with eGFR< 60
7. Obesity where girth exceeds the scanner bore
8. Pregnancy or breastfeeding
9. Inability to lie flat for CMR scan
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method